August 31, 2020 _ Online 8_30am -6_30pm EDT _ 5_30am - 3_30pm PDT

8:30 am Chair’s Opening Remarks

TIL- Growth & Modification

8:45 am Investigating TIL’s TCR Repertoire & Strategies for Their Isolation

9:10 am Enhancing the Function of Tumor-Specific T-Cells Through the Expression of Co-Stimulatory Chimeric Switch Receptors (CSR)

  • Cyrille Cohen Professor & Vice Dean at Faculty of Life Sciences, Bar-llan University

Synopsis

  • Explaining the importance of co-stimulatory signals in T-cells
  • Recalling the possibility to improve patient T-cells function through the manipulation of co-stimulatory pathways
  • Detailing the basics of design and use of co-stimulatory chimeric switch receptors to convert inhibitory signals into activation one

9:35 am Understanding the Landscape of Neoantigen Targeting in TIL Therapy

Synopsis

• Comparing the frequency of neo-antigen-specific and tumorreactive
TILs in situ and after in vitro expansion
• Forecasting the fate of suboptimal in-vitro expansion of clinicallyrelevant
TILs
• Describing transcriptomic signatures driving cell persistence and
tumor infiltration post ACT.

10:00 am TIL- Growth and Modification Q&A + Open Counsel

  • Anna Pasetto Assistant Professor, Karolinska Institutet
  • Cyrille Cohen Professor & Vice Dean at Faculty of Life Sciences, Bar-llan University
  • Alexandre Harari Associate Director of Scientific Affairs , UNIL/CHUV

10:15 am Morning Refreshments & Speed Networking

Synopsis

Virtual Speed Networking
Recreating the face-to-face networking in the virtual
world. We will pair you up with fellow attendees to break
the ice and make new business relationships!

Morning Networking
• Explore Demo Area and Virtual Booths
• 1-1 Meetings

Clinical TIL Treatment: Addressing the Combination, Order & Impact of Therapeutic Approaches

10:45 am PANEL: Combinational Approaches with TIL therapy

  • Jessica Chacon Assistant Prof, Texas Tech University Health Sciences Center
  • Anna Pasetto Assistant Professor, Karolinska Institutet
  • Marco Donia Clinician-Scientist, Associate Professor of Clinical Oncology, CCIT-DK National Center for Cancer Immune Therapy

Synopsis

  • Comparing methodologies to treat solid tumors with various combinatory approaches to improve TIL
    efficacy
  • Discussing the order and dosing procedures for alternative approaches
  • Considering the various ways of modifying TILs

11:15 am Investigating the Impact of Various Lymphodepleting Regiments Prior to TIL Therapy

Synopsis

  • Exploring the clinical preconditioning required before treatment.
  • Describing the bone marrow ablation, recovery and toxicity of
    treatment options

11:40 am TILT -123 in Phase 1 Clinical Trials. Concurrent TIL & Oncolytic Viral Therapy.

  • Riikka Havunen Head of Research And Development, TILT Biotherapeutics

Synopsis

  • Interpreting current clinical evidence and extrapolating the benefits
  • Describing mechanistic action of oncolytic virus
  • Considering changes in the tumor microenvironment and TIL response
    from viral treatment

12:05 pm Maximizing TIL Efficacy: Where to Position TIL Therapy

  • Marco Donia Clinician-Scientist, Associate Professor of Clinical Oncology, CCIT-DK National Center for Cancer Immune Therapy

Synopsis

  • Addressing the current melanoma treatment landscape and the
    stage which TILs are best used.
  • Reviewing TIL activity before and after checkpoint inhibitors

12:30 pm Clinical TIL Treatment: Addressing the Combination, Order & Impact of Therapeutic Approaches Q&A + Open Counsel

  • Michal Besser Laboratory Director, Sheba Medical Center
  • Riikka Havunen Head of Research And Development, TILT Biotherapeutics
  • Marco Donia Clinician-Scientist, Associate Professor of Clinical Oncology, CCIT-DK National Center for Cancer Immune Therapy

12:45 pm Networking Lunch

Synopsis

  • Explore Demo Area and Virtual Booths

Manufacturing & Operational Challenges

1:45 pm Streamlining TIL Therapy for Melanoma Treatment.

Synopsis

  • Adapting the process of growing TIL for robust expansion of TIL from any tumor type
  • Functional improvement of TIL through TGF-β signalling blockade
  • Clinical effectiveness of TIL

2:10 pm Iovance – advancing Advancing TIL Towards Commercialization

Synopsis

  • Delving into Iovance’s commercial success in the market
  • Sharing information regarding the four products in phase 2 trials.

2:35 pm Manufacturing & Operational Challenges Q&A + Open Counsel

2:45 pm Afternoon Networking

Synopsis

  • Explore Demo Area and Virtual Booths

3:15 pm PANEL: Discussing Other TIL Therapy Tumor Targets

Synopsis

  • Comparing research from various tumor target locations
  • Sharing various challenges specific to each tumor region
  • Collaborating in methods of overcoming diminished TIL products from certain cancer sites.

3:45 pm The Moffit Centre: TIL therapy in Clinical Care: Integrating Product to Patient

  • Amod Sarnaik Associate Professor of Cutaneous Oncology and Immunology, Moffitt Cancer Centre
  • John Mullinax Assistant Member of Surgical Oncology, Moffitt Cancer Center

Synopsis

  • Providing a pragmatic overview of clinical care
  • Divulging in the therapeutic contrasts for solid tumor treatments, including CAR-T and TCR therapy
  • Detailing their methodology for TIL identification and expansion strategy

4:15 pm Cooperative Q&A + Open Counsel with Moffit Cancer Center

4:30 pm Last networking opportunity.

4:45 pm Adoptive T cell Therapy at the Princess Margaret Cancer Centre

  • Linh Nguyen Staff Scientist & Head of Cell Manufacturing Team, Princess Margaret Cancer Centre

Synopsis

  • Describing adoptive T cell therapy trials with in-house cell manufacturing
  • Describing work in melanoma and solid tumors

5:15 pm CRISPR/Cas9-Engineered Tumor Infiltrating Lymphocyte (eTILTM) Therapies for Solid Tumors

Synopsis

  • Systematic identification of genes restoring and amplifying T cell
    function in the tumor microenvironment
  • Divulging updates on KSQ-001 and next generation TIL approaches
  • Lessons learnt from the use of CRISPR/Cas9 for T cell rejuvenation
    and enhanced stability within the tumor microenvironment

5:40 pm Humanized TIL/PDX Models to Study Patient-Specific Response to Immunotherapy

  • Sarah Gitto Postdoctoral Researcher, University of Pennsylvania School of Medicine

Synopsis

  • Providing examples and techniques of modelling use for patient
    xenograph models
  • Detailing cell culture and rapid expansion growth models with IL factors
  • Evaluation of patient-specific response to immune checkpoint inhibitors

6:05 pm TIL therapies: At the cellular level Q&A + Open Counsel

  • Micah Benson Head of Immunology, KSQ Therapeutics
  • Sarah Gitto Postdoctoral Researcher, University of Pennsylvania School of Medicine

6:15 pm Chair’s Closing Remarks

6:30 pm End of Day

Copy of Copy of 19859 TILs SEO Banner